Welcome to our dedicated page for Ovid Therapeutics SEC filings (Ticker: OVID), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ovid Therapeutics Inc. (Nasdaq: OVID) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Ovid is a New York‑based biopharmaceutical company developing small molecule medicines for brain conditions driven by neuronal hyperexcitability, and its filings offer detailed insight into this strategy, its capital structure and governance.
Investors can review current reports on Form 8‑K, where Ovid reports material events such as positive Phase 1 data for OV329 and OV350, leadership succession plans, private placement financing agreements involving Series B convertible preferred stock and warrants, and transactions like the sale of future ganaxolone royalty rights to Immedica Pharma AB. Other 8‑K items describe Nasdaq listing compliance developments, including bid price notifications, transfers to the Nasdaq Capital Market and subsequent confirmations of regained compliance.
Definitive proxy statements on Schedule 14A, such as the company’s special meeting materials, outline proposals to increase authorized common shares, approve conversions of preferred stock and warrant exercises related to PIPE financings, and authorize reverse stock split ranges. These documents also describe how Ovid seeks stockholder approval for securities issuances under Nasdaq listing rules.
Through Stock Titan, users can monitor Ovid’s real‑time filing activity from EDGAR, including 10‑K and 10‑Q reports when available, as well as Forms 3, 4 and 5 that disclose insider holdings and transactions. AI‑powered tools help summarize lengthy filings, highlight key sections on clinical pipeline strategy, financing terms, listing status and executive arrangements, and make it easier to interpret complex legal and financial language.
For anyone analyzing OVID stock, this filings page serves as a centralized view of Ovid Therapeutics’ official regulatory record, spanning clinical updates, capital markets transactions, governance decisions and listing‑related communications.
Ovid Therapeutics (NASDAQ:OVID) has amended its Exclusive Patent License Agreement with Immedica Pharma AB through Amendment No. 1, effective June 23, 2025. The key modification involves Immedica purchasing ongoing royalty obligations for $7.0 million in cash, payable within 10 business days. The original agreement granted Marinus (now an Immedica subsidiary) exclusive rights to ganaxolone for CDKL5 deficiency disorder treatment in the US and Europe. The amendment also provides Immedica with additional patent prosecution rights and anticipates a second amendment within six months to expand territory coverage and rights to other necessary patents.
Form 4 overview: Director Kevin J. Fitzgerald of Ovid Therapeutics Inc. (NASDAQ: OVID) reported the grant of a stock option for 45,000 shares on 02/20/2025 at an exercise price of $0.57 per share.
The option is classified as an acquisition (Code “A”) of derivative securities. It will vest 100 % on 02/20/2026, provided the director remains in continuous service, and will expire on 02/19/2035. Following the transaction, Fitzgerald beneficially owns 45,000 derivative securities, all held directly.
No common-stock transactions, sales, or additional derivative dispositions were reported. Because this filing reflects a routine director equity grant rather than an open-market purchase or sale, it typically has limited immediate trading impact but does strengthen long-term alignment between the director and shareholders.
Form 4 Filing Details: Bart Friedman, Director of Ovid Therapeutics (OVID), received a stock option grant for 45,000 shares of common stock on February 20, 2025. The filing was reported on June 28, 2025.
Key Transaction Terms:
- Option exercise price set at $0.57 per share
- Options will vest fully on February 20, 2026, contingent on continuous service
- Options expire on February 19, 2035
- Transaction reported as a Direct (D) ownership
This grant appears to be part of the company's director compensation program. The significant discount in the exercise price compared to typical market prices could indicate either a period of stock price decline or a deliberate incentive structure to align director interests with shareholders.
Insider Trading Alert: Barbara Gayle Duncan, Director at Ovid Therapeutics (OVID), received a stock option grant on February 20, 2025. The transaction details include:
- Granted 45,000 stock options to purchase common stock
- Exercise price set at $0.57 per share
- Options will vest fully on February 20, 2026, contingent on continuous service
- Options expire on February 19, 2035
This Form 4 filing, reported by the director's attorney-in-fact Jason Minio on June 18, 2025, represents a standard equity compensation grant for board service. The relatively low exercise price and one-year cliff vesting schedule suggest this is part of the company's regular director compensation program.
Ovid Therapeutics director Karen Bernstein received a stock option grant for 45,000 shares of common stock on February 20, 2025. The key details of this Form 4 filing include:
- Option exercise price set at $0.57 per share
- Options will vest fully on February 20, 2026, contingent on continuous service
- Expiration date is set for February 19, 2035
- The derivative securities are held directly by the reporting person
This grant represents a standard director compensation package and aligns the director's interests with shareholders through long-term equity incentives. The one-year cliff vesting schedule encourages retention while the ten-year exercise window provides flexibility in execution timing.